uso basal
uso basal de SGLT2i (estudio STEP-HF). Existen otros escenarios de potencial beneficio con esta asociación de fármacos, como el síndrome de apnea-hipopnea obstructiva del sueño, y la enfermedad de hígado graso no alcohólico metabólica (MAFLD), donde diversos ensayos clínicos brindarán datos exactos del beneficio clínico. Conclusión Hemos comprobado que la asociación de estos dos grupos de fármacos es segura y potencialmente puede asociarse con un beneficio clínico incremental. En la mayoría de los escenarios, esta combinación es eficaz y debería implementarse para reducir la carga de enfermedad cardiovascular global. Bibliografía sugerida • 1. Gourdy P, Darmon P, Dievart F, Halimi JM, Guerci B. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). Cardiovascular Diabetology. 2023 Dec;22(1):1-4. • 2. Brown E, Heerspink HJ, Cuthbertson DJ, Wilding JP. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. The Lancet. 2021 Jul 17;398(10296):262-76. • 3. Gómez-Huelgas R, Sanz-Cánovas J, Cobos-Palacios L, López-Sampalo A, Pérez-Belmonte LM. Glucagon-like peptide-1 receptor agonists and sodiumglucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect. European Journal of Internal Medicine. 2022 Feb 1;96:26-33. • 4. Gorgojo-Martínez JJ. New glucose-lowering drugs for reducing cardiovascular risk in patients with type2 diabetes mellitus. Hipertension y Riesgo Vascular. 2019 May 10;36(3):145-61. • 5. Bonaventura A, Carbone S, Dixon DL, Abbate A, Montecucco F. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists. Journalofinternal medicine. 2019 Jul;286(1):16-31. • 6. Hussein H, Zaccardi F, Khunti K, Davies MJ, Patsko E, Dhalwani NN, Kloecker DE, Ioannidou E, Gray LJ. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. Diabetes, Obesity and Metabolism. 2020 Jul;22(7):1035-46. • 7. Kyriakos G, Quiles-Sanchez LV, Garmpi A, Farmaki P, Kyre K, Savvanis S, Antoniou VK, Memi E. SGLT2 inhibitors and cardiovascular outcomes: do they differ or there is a class effect? New insights from the EMPA-REG OUTCOME trial and the CVD-REAL study. CurrentCardiologyReviews. 2020 Nov 1;16(4):258- 65. • 8. Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017 Jul 18;136(3):249-59. • 9. Cosentino F, Cannon CP, Cherney DZ, Masiukiewicz U, Pratley R, Dagogo-Jack S, Frederich R, Charbonnel B, Mancuso J, Shih WJ, Terra SG. Efficacy of ertugliflozin on heart failure–related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV Trial. Circulation. 2020 Dec 8;142(23):2205-15. • 10. DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes, Obesity and Metabolism. 2017 Oct;19(10):1353-62. 14 // EDITORIAL SCIENS
